Dr. SOFIE JAMAR
ActiveSummary
Dr. SOFIE JAMAR has been active since 2007 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €487,853 and a net result of €123,668. Equity is growing by about 19% per year across the filed financial years. The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
- Equity
- €487,853
- Profit
- €123,668
- JAMAR Sofie AnnDirector
- PERSOONS Steven Julienne PaulDirector
Why 95lowers riskSize: total assets €517,303Equity €487,853 (94.3% of total assets)Figures for financial year 2025 (filed 30-04-2026)Founded in 2007Show the evidence
Checked score
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (no NACE code, micro): better than 81% on solvency, 58% on liquidity, 78% on profitability and 16% on growth.
The bankruptcy probability was computed on 29-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
This company filed its last 7 accounts on average 100 days before the deadline; the Belgian median for financial year 2024 is 4 days before the deadline, and 38% of all filings were late.
Searched, nothing found (2)
- Annual accounts filedfinancial year 2025 · micro…
- Annual accounts filedfinancial year 2024 · micro…
- Highest result from 2018 to 2025net €131,899 ▲11.2%
Financials · financial year 2025, micro format
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
The operating result falls in 2025; 2025 is 4% below 2024.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Use the arrow keys on the chart for the figures per year.
Peer companies
Historical observationOf the 17,811 companies that looked in July 2024 the way this one looks now, 0.3% went bankrupt within 24 months and 96.5% are still going.
- Small
- 10 to 20 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
For this company itself Checked computes a bankruptcy probability of 0.1% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 17,811 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | €641 | €646 | €1,737 | €734 | €757 | ▲ 3.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €32,278 | €34,889 | €18,938 | €43,435 | €47,353 | €43,129 | €36,093 | €45,785 | ▲ 26.9% |
| Other operating charges640/8 | - | - | - | €1,147 | €804 | €1,031 | €875 | €940 | ▲ 7.4% |
| Gross operating margin9900 | €142,288 | €157,788 | €162,858 | €168,368 | €189,920 | €211,227 | €220,475 | €223,216 | ▲ 1.2% |
| Operating profit (loss)9901 | €108,797 | €121,090 | €142,764 | €123,785 | €141,763 | €167,068 | €183,508 | €176,491 | ▼ 3.8% |
| Financial income75/76B | - | - | - | €36 | €875 | €3,823 | €6,179 | €3,507 | ▼ 43.2% |
| Recurring financial income75 | €110 | €11 | - | €36 | €875 | €3,823 | €6,179 | €3,507 | ▼ 43.2% |
| Financial charges65/66B | - | - | - | €45 | €79 | €48 | €58 | €918 | ▲ 16× |
| Recurring financial charges65 | €1,089 | €234 | €64 | €45 | €79 | €48 | €58 | €918 | ▲ 16× |
| Profit (loss) for the period before taxes9903 | €107,818 | €120,867 | €142,700 | €123,777 | €142,559 | €170,842 | €189,628 | €179,080 | ▼ 5.6% |
| Income taxes67/77 | €32,661 | €39,224 | €42,992 | €35,815 | €43,128 | €52,247 | €57,729 | €55,412 | ▼ 4.0% |
| Profit (loss) for the period9904 | €75,157 | €81,643 | €99,708 | €87,961 | €99,431 | €118,595 | €131,899 | €123,668 | ▼ 6.2% |
| Profit (loss) for the period to be appropriated9905 | €75,157 | €81,643 | €99,708 | €87,961 | €99,431 | €118,595 | €131,899 | €123,668 | ▼ 6.2% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €263,202 | €278,351 | €379,148 | €386,500 | €479,958 | €592,703 | €647,586 | €517,303 | ▼ 20.1% |
| Fixed assets21/28 | €65,352 | €46,328 | €139,241 | €169,283 | €129,715 | €94,036 | €149,655 | €144,433 | ▼ 3.5% |
| Tangible fixed assets22/27 | €65,352 | €46,328 | €139,241 | €169,283 | €129,715 | €94,036 | €149,655 | €144,433 | ▼ 3.5% |
| Land and buildings22 | - | - | - | €25,412 | €22,464 | €19,516 | €16,568 | €30,273 | ▲ 82.7% |
| Plant, machinery and equipment23 | - | - | - | €9,124 | €11,132 | €11,672 | €23,254 | €22,604 | ▼ 2.8% |
| Furniture and vehicles24 | - | - | - | €134,747 | €96,119 | €62,849 | €109,834 | €91,556 | ▼ 16.6% |
| Current assets29/58 | €197,850 | €232,023 | €239,907 | €217,217 | €350,242 | €498,667 | €497,931 | €372,870 | ▼ 25.1% |
| Amounts receivable after more than one year29 | - | - | - | - | €140,000 | €260,000 | €260,000 | €100,000 | ▼ 61.5% |
| Other amounts receivable291 | - | - | - | - | €140,000 | €260,000 | €260,000 | €100,000 | ▼ 61.5% |
| Amounts receivable within one year40/41 | €28,664 | €30,607 | €19,714 | €35,290 | €33,488 | €4,454 | €4,774 | €6,311 | ▲ 32.2% |
| Trade receivables40 | - | - | - | €31,105 | €33,488 | €4,454 | €4,774 | €3,150 | ▼ 34.0% |
| Other amounts receivable41 | - | - | - | €4,185 | - | - | - | €3,160 | - |
| Current investments50/53 | - | - | - | - | - | - | €99,617 | €199,732 | ▲ 101% |
| Cash at bank and in hand54/58 | €169,187 | €199,014 | €217,772 | €181,474 | €173,268 | €229,929 | €124,788 | €45,375 | ▼ 63.6% |
| Deferred charges and accrued income490/1 | - | - | - | €452 | €3,487 | €4,284 | €8,753 | €21,452 | ▲ 145% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €263,202 | €278,351 | €379,148 | €386,500 | €479,958 | €592,703 | €647,586 | €517,303 | ▼ 20.1% |
| Equity10/15 | €224,650 | €248,070 | €347,778 | €373,515 | €460,884 | €579,480 | €633,497 | €487,853 | ▼ 23.0% |
| Contributions10/11 | €12,400 | €12,400 | - | €12,400 | €12,400 | €12,400 | €12,400 | €12,400 | = |
| Reserves13 | €212,250 | €235,670 | €335,378 | €361,115 | €448,484 | €567,080 | €621,097 | €475,453 | ▼ 23.4% |
| Non-distributable reserves130/1 | - | - | - | €1,860 | €1,860 | - | - | - | - |
| Reserves not available under the articles1311 | - | - | - | €1,860 | €1,860 | - | - | - | - |
| Distributable reserves133 | - | - | - | €359,255 | €446,624 | €567,080 | €621,097 | €475,453 | ▼ 23.4% |
| Amounts payable17/49 | €38,553 | €30,282 | €31,370 | €12,985 | €19,073 | €13,224 | €14,089 | €29,450 | ▲ 109% |
| Amounts payable after more than one year17 | €3,177 | - | - | - | - | - | - | - | - |
| Amounts payable within one year42/48 | €35,375 | €30,282 | €31,370 | €12,985 | €19,073 | €13,224 | €14,089 | €28,203 | ▲ 100% |
| Trade debts44 | €12,305 | €16,745 | €12,017 | €10,761 | €13,721 | €5,864 | €8,265 | €20,255 | ▲ 145% |
| Suppliers440/4 | - | - | - | €10,761 | €13,721 | €5,864 | €8,265 | €20,255 | ▲ 145% |
| Taxes, remuneration and social security45 | - | - | - | €900 | €4,028 | €6,275 | €5,409 | €7,948 | ▲ 46.9% |
| Taxes450/3 | - | - | - | - | €3,128 | €5,375 | €4,509 | €7,048 | ▲ 56.3% |
| Remuneration and social security454/9 | - | - | - | €900 | €900 | €900 | €900 | €900 | = |
| Other amounts payable47/48 | - | - | - | €1,324 | €1,324 | €1,085 | €415 | - | - |
| Accrued charges and deferred income492/3 | - | - | - | - | - | - | - | €1,246 | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €75,157 | €81,643 | €99,708 | €87,961 | €99,431 | €118,595 | €131,899 | €123,668 | ▼ 6.2% |
| + Depreciation and write-downs630 | €32,278 | €34,889 | €18,938 | €43,435 | €47,353 | €43,129 | €36,093 | €45,785 | ▲ 26.9% |
| Operating cash flow (approximation) | €107,435 | €116,532 | €118,646 | €131,396 | €146,784 | €161,724 | €167,992 | €169,453 | ▲ 0.9% |
| Investment in fixed assets (approximation) | - | -€15,866 | -€111,851 | -€73,477 | -€7,785 | -€7,450 | -€91,712 | -€40,563 | ▲ 55.8% |
| Change in cash | - | €29,827 | €18,758 | -€36,298 | -€8,207 | €56,661 | -€105,141 | -€79,413 | ▲ 24.5% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Latest 10 of 18 filings with the National Bank
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | micro format | 29-04-2026 | 2026-00095613 |
| 31-12-2024 | micro format | 29-04-2025 | 2025-00079180 |
| 31-12-2023 | micro format | 24-04-2024 | 2024-00067519 |
| 31-12-2022 | micro format | 03-03-2023 | 2023-00034819 |
| 31-12-2021 | micro format | 20-05-2022 | 2022-20032580 |
| 31-12-2020 | micro format | 19-02-2021 | 2021-05700276 |
| 31-12-2019 | micro format | 26-06-2020 | 2020-21900005 |
| 31-12-2018 | micro format | 22-06-2019 | 2019-21800455 |
| 31-12-2017 | micro format | 12-06-2018 | 2018-17900057 |
| 31-12-2016 | micro format | 26-06-2017 | 2017-21500109 |
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.
Directors
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| JAMAR Sofie Ann |
|
| PERSOONS Steven Julienne Paul |
|
Owners and capital
Capital and shareholders
- 21-11-2023 Converted to unavailable equity
Group and network
Connections & network
2 current directorsThe network starts from this company’s directors. Other companies they run appear here as nodes.
History
Acts, filings and financial milestones
21-11
Gazette deed
Resignations: JAMAR Sofie Ann (manager) and PERSOONS Steven Julienne Paul (manager)Reappointments: JAMAR Sofie Ann (director) and PERSOONS Steven Julienne Paul (director) · Capital · Power of attorney13 facts ▸
- Capital
- Director resignation, JAMAR Sofie Ann (manager)
- Director resignation, PERSOONS Steven Julienne Paul (manager)
- Director reappointment, JAMAR Sofie Ann (director (not named in the articles))
- Director reappointment, PERSOONS Steven Julienne Paul (director (not named in the articles))
- Other provision, “uitoefening mandaat, kwijting aan ontslagnemende zaakvoerders” (deed in Dutch)
- Power of attorney
- General meeting, 15-11-2023
- Other provision, “aanpassing statuten aan WVV en behoud rechtsvorm, statuten aanpassen en rechtsvorm besloten vennootschap behouden” (deed in Dutch)
- Registered office clause, “Vlaams Gewest, adresverwijzing in statuten” (deed in Dutch)
- Capital conversion, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Reserve release, “opheffen statutair onbeschikbare eigen vermogensrekening en beschikbaar maken voor uitkering, vormen en meerderheden statutenwijziging” (deed in Dutch)
- +1 further fact in this act
Show earlier events
About the unread acts
Of the 3 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.
Register details
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 29 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
Recognitions · licences · registrations
Legal Entity Identifier
Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.
Sites & property
1 establishment unit
2 parcels
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 12005B0315/00R000 | Flanders | 1,434 m² | 1 · 238 m² | 6.5 m · 1 |
| 12005B0315/00A002 | Flanders | 787 m² | 1 · 164 m² | 11.0 m · 2 |
How the parcels are linked
Articles of association
What the company does
- PurposeThe activities the company may carry out under its articles.
- “De uitoefening van de geneeskunde met specialisatie inwendige ziekten en nierziekten,met inachtneming van de regels van de medische…” (deed in Dutch)
17 activities (deed in Dutch)
- De uitoefening van de geneeskunde met specialisatie inwendige ziekten en nierziekten,met inachtneming van de regels van de medische deontologie.
- De aandeelhouder oefent zijn volledige medische activiteit uit in naam en voor rekening van de vennootschap.
- Het verstrekken van adviezen en raadgevingen.
- De professionele aansprakelijkheid van de arts-aandeelhouder is onbeperkt.
- Deze activiteiten worden uitgeoefend met eerbiediging van de deontologische en administratieve voorschriften,volgens de principes van de medische ethiek en de eisen van de wetenschappelijke discipline.Meer bepaald zal de vrije artsenkeuze in hoofde van de patiënt,de diagnostische en therapeutische vrijheid alsook het respect voor het medisch beroepsgeheim behouden blijven.
- De vennootschap waakt erover dat de onafhankelijkheid van de aandeelhouder in de uitoefening van zijn beroep gewaarborgd blijft;
- Het inrichten van algemene diensten en een medisch secretariaat in het bijzonder,die nodig of nuttig zijn voor de uitoefening van voornoemde activiteiten.
- De aankoop,het huren,leasen en invoeren van alle medische apparatuur en begeleidende accommodaties,inclusief gebouwen en transportmiddelen,voor voornoemde activiteiten,kortom van een volledige materiële infrastructuur voor de praktijk van de arts-aandeelhouder.
- Het aanleggen van reserves,nodig tot het aanschaffen van alle dienstige apparatuur,gebouwen en transportmiddelen noodzakelijk en bevorderlijk voor het uitoefenen van alle bovenvermelde beroepsactiviteiten door de arts-aandeelhouder.
- De mogelijkheid scheppen om de aandeelhouder toe te laten zich verder te bekwamen in voormelde medische disciplines,dit teneinde een kwalitatief hoogstaande praktijkuitoefening mogelijk te maken.
- Bovendien kan de vennootschap informatie verstrekken en of onderricht geven,zonder dat dit de vorm van een aanvullende commerciële activiteit mag aannemen.
- De vennootschap mag samenwerken met alle ondernemingen die een gelijkaardig voorwerp nastreven,maar overeenkomsten die artsen niet mogen afsluiten met andere artsen of met derden,zullen evenmin door de vennootschap mogen afgesloten worden.
- Aldus zal de vennootschap geen deelnemingen mogen bezitten van een andere artsenvennootschap waarbinnen een medische activiteit wordt uitgeoefend.
- De vennootschap kan deelnemen in kostenassociaties of middelenvennootschappen van artsen,of lid zijn van een vereniging zonder winstgevend doel van artsen.
- De vennootschap mag als bijkomstig voorwerp,beleggen in roerende of onroerende goederen,mits dit een beheren is van de roerende en onroerende goederen als een voorzichtig en redelijk persoon,en zonder dat dit op geen enkel ogenblik aanleiding mag geven tot het ontwikkelen van welke commerciële activiteit ook.
- Wanneer er meerdere aandeelhouders zijn,dienen de beslissingen in verband met het investeringsbeleid te gebeuren met unanimiteit van stemmen.
- De vennootschap zal in het algemeen alle burgerlijke,roerende of onroerende handelingen mogen verrichten in rechtstreeks verband met haar maatschappelijk voorwerp of welke van die aard zouden zijn dat zij het bereiken ervan rechtstreeks,geheel of ten dele vergemakkelijken,dit alles rekening houdend met de medische deontologie ter zake.
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- DR.SOFIE JAMAR
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaams Gewest, bij enkel besluit bestuursorgaan in België of buitenland” (deed in Dutch)
Who represents it, and how
- Who signsWho may bind the company towards others, for example by signing a contract.
- “De vennootschap wordt ten overstaan van derden, in en buiten rechte, in alle rechtshandelingen en akten, met inbegrip van die akten die de…”
- Board ruleHow the board is made up, meets and takes decisions.
- “Één of meerdere bestuurders, niet-statutaire bestuurder ad nutum herroepbaar bij gewone meerderheid” (deed in Dutch)
Capital, shares and profit
- Kind of sharesWhich classes of shares exist and what rights each class carries.
- “Register van aandelen op naam, volgnummer” (deed in Dutch)
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- “Rechten waarvan overdracht wordt voorgesteld, bestuursorgaan” (deed in Dutch)
- Share issue ruleHow and by whom new shares can be issued.
- “Inbreng in geld met uitgifte van nieuwe aandelen - recht van voorkeur, naar evenredigheid van het aantal aandelen dat zij bezitten” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- First Tuesday of June at 20:00
Oversight and winding up
- Dissolution ruleWhen and by whom the company can be dissolved.
- One provision in the deed
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- One provision in the deed